The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients

Canadian Journal of Cardiology

Volumn 32, Issue 3, 2016, Pages 336-343

  Angaran, Paul ^a   Dorian, Paul ^a   Tan, Mary K ^b   Kerr, Charles R ^c   Green, Martin S ^d   Gladstone, David J ^e   Mitchell, L Brent ^f   Fournier, Carl ^g   Cox, Jafna L ^h   Talajic, Mario ⁱ   Lin, Peter J ^b,j   Langer, Anatoly ^b   Goldin, Lianne ^b   Goodman, Shaun G ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b CANADIAN HEART RESEARCH CENTRE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g NOTRE DAME HOSPITAL   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ MONTREAL HEART INSTITUTE   (Canada)

^j Lincorp Medical Inc   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; CLOPIDOGREL; WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DRUG USE; FEMALE; GENERAL PRACTITIONER; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RISK ASSESSMENT; CANADA; COMPLICATION; INCIDENCE; PATIENT EDUCATION; PROGNOSIS; RISK FACTOR; STROKE; SURVIVAL RATE; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CANADA; FEMALE; HUMANS; INCIDENCE; MALE; PATIENT EDUCATION AS TOPIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE; SURVIVAL RATE;

EID: 84959499512     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.07.012     Document Type: Article

References (23)

1. Atrial Fibrillation Statistics - Heart and Stroke Foundation of Ontario. Available at: Accessed November 26, 2014. http://www.heartandstroke.on.ca/site/c.pvI3IeNWJwE/b.3581729/k.359A/Statistics.htm#atrialfib.
2. Gladstone D.J., Bui E., Fang J., et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009, 40:235-240.
3. Cairns J.A., Connolly S., McMurtry S., Stephenson M., Talajic M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011, 27:74-90.
4. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
5. Verma A., Cairns J.A., Mitchell L.B., et al. 2014 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol 2014, 30:1114-1130.
6. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke. JAMA 2001, 285:2864-2870.
7. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010, 137:263-272.
8. Pisters R., Lane D.A., Nieuwlaat R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest 2010, 138:1093-1100.
9. Rosendaal F.R., Cannegieter S.C., van der Meer F.J., Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.
10. 2 Score. Chest 2013, 144:1555-1563.
11. De Caterina R., Husted S., Wallentin L., et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013, 110:1087-1107.
12. Stroke Risk in Atrial Fibrillation Working Group Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008, 39:1901-1910.
13. Camm A.J., Kirchhof P., Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429.
14. Lip G.Y., Nielsen P.B., Skjoth F., Rasmussen L.H., Larsen T.B. Atrial fibrillation patients categorized as "not for anticoagulation" according to the 2014 Canadian Cardiovascular Society Algorithm are not "low risk.". Can J Cardiol 2015, 31:24-28.
15. Cairns J.A., Healey J.S., Macle L., Mitchell L.B., Verma A. The new Canadian Cardiovascular Society Algorithm for antithrombotic therapy of atrial fibrillation is appropriately based on current epidemiologic data. Can J Cardiol 2015, 31:20-23.
16. Steinberg B.A., Kim S., Thomas L., et al. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation 2014, 129:2005-2012.
17. Man-Son-Hing M., Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians's fears often unfounded. Arch Intern Med 2003, 163:1580-1586.
18. Gage B.F., Yan Y., Milligan P.E., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151:713-719.
19. Fang M.C., Go A.S., Chang Y., et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 2011, 58:395-401.
20. Atarashi H., Inoue H., Okumura K., et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation. A report from the J-RHYTHM Registry. Circ J 2011, 75:1328-1333.
21. Ogilvie I.M., Newton N., Welner S.A., Cowell W., Lip G.Y. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010, 123:638-645.
22. Mahmud A., Bennett K., Okechukwu I., Feely J. National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. Br J Clin Pharmacol 2007, 64:706-709.
23. Lip G.Y., Laroche C., Ioachim P.M., et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot phase (EORP-AF Pilot registry). Eur Heart J 2014, 35:3365-3376.